Botulism [Clostridium botulinum] [serotype A, B, C, D, E, F, G] (heptavalent) antitoxin [equine] is a Antibody owned by Emergent BioSolutions, and is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing.

The mechanism of action of BAT is through passive immunization with equine polyclonal antibody fragments (primarily F(ab')2 and Fab) against botulinum neurotoxin (BoNT) A, B, C, D, E, F, and G. In the circulation the polyclonal antibody fragments bind to free BoNT. This prevents the BoNT from interacting with ganglioside anchorage sites and protein receptors on the cholinergic nerve endings. In turn this prevents BoNT internalization into the target cells. The antibody/antigen complexes are then cleared from the circulation by the organs involved in processing immune complexes.

The revenue for Botulism [Clostridium botulinum] [serotype A, B, C, D, E, F, G] (heptavalent) antitoxin [equine] is expected to reach a total of $410m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Botulism [Clostridium botulinum] [serotype A, B, C, D, E, F, G] (heptavalent) antitoxin [equine] NPV Report.

Botulism [Clostridium botulinum] [serotype A, B, C, D, E, F, G] (heptavalent) antitoxin [equine] is currently owned by Emergent BioSolutions.

Botulism [Clostridium botulinum] [serotype A, B, C, D, E, F, G] (heptavalent) antitoxin [equine] Overview

Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) (Equine) (BAT) belongs to anti-toxins. It is a sterile solution of F(ab’) 2  and F(ab') 2 -related antibody fragments prepared from plasma obtained from horses that have been immunized with a specific serotype of botulinum toxoid and toxin. It is formulated as sterile injectable solution for injection for intravenous route of administration.  Botulism Antitoxin Heptavalent (BAT) is indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients.

Emergent BioSolutions Overview

Emergent BioSolutions (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises, and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent’s pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.

The company reported revenues of (US Dollars) US$1,792.7 million for the fiscal year ended December 2021 (FY2021), an increase of 15.3% over FY2020. In FY2021, the company’s operating margin was 19.7%, compared to an operating margin of 27.9% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 19.6% in FY2020. The company reported revenues of US$240 million for the third quarter ended September 2022, a decrease of 1.1% over the previous quarter.

Quick View – Botulism [Clostridium botulinum] [serotype A, B, C, D, E, F, G] (heptavalent) antitoxin [equine]

Report Segments
  • Innovator (NME)
Drug Name
  • Botulism [Clostridium botulinum] [serotype A, B, C, D, E, F, G] (heptavalent) antitoxin [equine]
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.